

IASLC 2022 World Conference on Lung Cancer
Industry-sponsored symposium
Vienna, Austria (WCLC 2022)

Is it time to raise the bar for **ALK+ NSCLC** patients?

Saturday 6th August, 2022 | 14:30–15:30 CET
Hall C2

Messe Wien Exhibition & Congress Center, Vienna, Austria



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology Industry-sponsored Symposium at WCLC 2022, entitled **"Is it time to raise the bar for ALK+ NSCLC patients?"**

We are delighted to be holding this **live, discussion-based, highly interactive symposium** where you will have the opportunity to participate in roundtable discussions.

During the symposium we will review the latest data and expectations for first-line ALK+ NSCLC therapy and discuss how to effectively manage adverse events during treatment. The faculty will also share perspectives on post-progression options in ALK+ NSCLC and discuss what the future might hold in this field.

My colleagues and I look forward to welcoming you for what promises to be an engaging and thought-provoking symposium.

Dr Justin Gainor, Chair

Center for Thoracic Cancers, Massachusetts General Hospital, Boston, USA

Program

Chair: **Dr Justin Gainor (USA)**

14:30–14:35	Welcome and introduction	Dr Justin Gainor (USA)
14:35–15:15	New data and updated expectations for first-line therapy	Dr Alessandra Bearz (Italy)
	Managing AEs and keeping patients on treatment	Dr Rosario García Campelo (Spain)
	What next? Options after progression on 2nd- and 3rd-generation TKIs	Dr Alessandra Bearz (Italy)
	The future of ALK+ NSCLC	Dr Justin Gainor (USA)
	<i>Each presentation will be followed by panel discussion</i>	
15:15–15:25	Q&A	All faculty, facilitated by Dr Justin Gainor (USA)
15:25–15:30	Summary and close	Dr Justin Gainor (USA)



This meeting is organized and sponsored by Pfizer.
© Pfizer Inc.
www.pfizer.com

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.
June 2022. PP-UNP-GLB-0166.